Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.01 from other evidence | 0.00 |
| cell type Human Protein Atlas | cell type enriched outside the brain (mast cells) | 0.10 |
| chemistry Open Targets | reachable by antibody | 0.45 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 1 Parkinson's papers of 201 | 0.91 |
| pathways Reactome | 1 pathway; mostly energy | 0.60 |
No case: the score is under the bar. Receipt 9892
Sealed predictions
- CPA3 in dopamine neurons, braak+0.40 (p 0.285) → +0.63 (p 0.068)receipt 9899
Swarm cases
receipt 9899: CPA3 in dopamine neurons, braak
- power
- full sample +0.42 (p 0.082, n 18), 95% CI -0.06 to +0.74. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: +0.44 (p 0.069, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.37 (p 0.132, n 18). could be the mix.
- skeptic
- leave-one-out range +0.34 to +0.53, sign flips 0; without severely affected donors +0.42 (p 0.082, n 18). robust.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for CPA3 in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts